Abstract 617P
Background
Ewing sarcoma is a neoplasm of neuroectodermal origin arising from bone or soft tissue. The annual incidence of Ewing sarcoma in children is 2.93 per 1,000,000. Acute myeloid leukaemia (AML) is one of the most common malignancies as a complication of primary cancer therapy. There are very few studies reported the association of Ewing sarcoma with AML. So, our aim is to quantify the risk of developing AML in Ewing sarcoma patients and provide updated evidence to the literature.
Methods
We extracted the data from the surveillance, Epidemiology and End Results (SEER) statistical analysis software package (SEER*Stat, version 8.4.1.2). We used the MP-SIR session to identify patients who had ewing sarcoma as a first primary tumor, then diagnosed with acute myeloid leukaemia as a second primary malignancy between 2000 and 2020. We assessed the SIR as Observed/Expected(O/E) and Excess Absolute Risk (EAR) per 10,000 with a 95% Confidence Interval (CI) and statistical significance at P<0.05.
Results
A total of 2631 patients had a median follow-up of 120+ months. Patient with Ewing sarcoma had an increased risk to develop AML with O/E of 145.98 (95% CI:101.68 -203.03, P<0.05, EAR= 21.79). The total cohort of patients had a PC of 32.7, APC of 1.3 (95% CI: 0.6 -2.0; P<0.05. Female patients had a PC of 46.5, APC of 1.7 (95% CI: 0.5 -2.9; P<0.05). about 35 patients developed acute non lymphocytic leukaemia (ANLL) with O/E 130.92 (95% [CI] 91.19 -182.08; P<0.05, EAR 21.77).
Conclusions
Ewing sarcoma is a very rare tumor that it is hard to assess the risk of multiple primary malignancies associated with it. In this study we found patients who developed a primary Ewing sarcoma had significantly high risk of developing Acute myeloid leukemia especially in the first year after diagnosis, so we recommend to start screening for AML once Ewing sarcoma is diagnosed for early detection and better management plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract